BEAM - BEAM

Beam Therapeutics

BEAM THERAPEUTICS INC

Beam Inc.

NYSE

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

Santa,Clara,,California,-,April,26,,2018:,Applied,Materials,Offices

News

Upgrades

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

AMAT

BEAM

CHKP

RACE

This Applied Materials Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday

Cathie Wood Offloads Meta Stock While Mark Zuckerberg Celebrates Llama AI Success

Equities

ETFs

ABSI

AMGN

ARKG

ARKK

ARKQ

ARKX

ILMN

IRDM

PACB

RPTX

VEEV

Cathie Wood-led Ark Invest made notable trades, buying IRDM, BEAM, PACB, ABSI and selling ILMN, RPTX, AMGN, VEEV.

Cathie Wood&#39;s Ark Invest Scoops Up Iridium, Beam, Pacific Biosciences While Offloading Illumina And Amgen

A,Vivid,Digital,Illustration,Showcasing,The,Revolutionary,Crispr-cas9,Gene,Editing

Biotech

Health Care

Financing

Offerings

Movers

General

Beam Therapeutics reports Phase 1/2 trial data showing BEAM-302&#39;s potential in AATD treatment, with dose-dependent mutation correction and sustained effects.

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

Beam Therapeutics Inc

BEAM - United States Dollar

BEAM COMM HLDGS LTD by BEAM COMMUNICATIONS HLDGS LTD.

Beam Global

Beamr Imaging Ltd

BEAMZ INTERACTIVE INC by Beamz Interactive Inc

Beamz Interactive Inc

Press Releases

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Earnings

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Beam Therapeutics Announces Pricing of Underwritten Offering

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Ascentage Pharma Group International - American Depository Shares

Ascentage Pharma Group

ACADIA Pharmaceuticals Inc. - Common Stock

ACADIA Pharmaceuticals

Agios Pharmaceuticals, Inc. - Common Stock

Agios Pharmaceuticals

Apogee Therapeutics

Arcutis Biotherapeutics, Inc. - Common stock

Arcutis Biotherapeutics

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

Biohaven

CG Oncology

Centessa Pharmaceuticals plc - American Depositary Shares

Centessa Pharmaceuticals

Denali Therapeutics

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Amicus Therapeutics

ImmunityBio

Disc Medicine

Janux Therapeutics

Kiniksa Pharmaceuticals, Ltd. - Class A Ordinary Shares

Kiniksa Pharmaceuticals

Kymera Therapeutics

Mirum Pharmaceuticals, Inc. - common stock

Mirum Pharmaceuticals

MoonLake Immunotherapeutics - Class A Ordinary Shares

MoonLake

NewAmsterdam Pharma Company N.V. - Ordinary Shares

NewAmsterdam Pharma Co

Recursion Pharmaceuticals, Inc. - Class A Common Stock

Recursion Pharmaceuticals

Travere Therapeutics, Inc. - Common Stock

Travere Therapeutics

Twist Bioscience Corporation - Common Stock

Twist Bioscience

Vericel

Veracyte

B of A Securities

Scotiabank

Jones Trading

HC Wainwright & Co.

Guggenheim

Comments

Beam Therapeutics

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga